Insuman Basal

Insulin Human, the active ingredient in Insuman Basal, is a long‑acting insulin presented as a 100 IU/mL injectable suspension for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients.

GNH USA supplies Insuman Basal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Basal is a long‑acting insulin used to manage blood glucose in diabetes mellitus.

- Type 1 diabetes mellitus: provides basal insulin coverage to maintain stable glucose levels between meals and overnight. - Type 2 diabetes mellitus: complements oral agents or rapid‑acting insulins to achieve target glycemic control. - Gestational diabetes mellitus (when indicated): offers basal insulin support under specialist supervision.

Insuman Basal may cause a range of adverse reactions.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling or itching at the injection site. - Weight gain: modest increase in body weight due to improved glucose utilization. - Lipodystrophy: localized thickening or loss of subcutaneous fat. - Edema: mild fluid retention, often in the lower extremities. - Headache: transient mild to moderate headache.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Anaphylactic reaction: rare systemic allergic response with rash, bronchospasm or hypotension. - Insulin allergy: localized or systemic hypersensitivity to the protein. - Hypokalemia: low potassium levels, particularly with high insulin doses. - Acute pancreatitis: very rare inflammation of the pancreas. - Serum sickness–like reaction: fever, arthralgia and rash.

When using Insuman Basal, consider the following safety measures.

- Dose titration: adjust dose based on regular glucose monitoring and clinical response. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose. - Renal impairment: monitor closely as insulin clearance may be reduced. - Pregnancy and lactation: use only if benefits outweigh potential risks and under specialist guidance. - Concomitant medications: review for agents that may mask hypoglycemia symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal can interact with several drug classes.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms and prolong its duration. - Monoamine oxidase inhibitors (MAOIs): can potentiate insulin’s glucose‑lowering effect. - Corticosteroids: may increase insulin resistance, requiring dose adjustments.

Moderate Interactions (Monitor Closely): - Oral hypoglycemics (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect, risk of hypoglycemia. - Diuretics (thiazides): may impair glucose tolerance, necessitating closer monitoring. - ACE inhibitors: may enhance insulin sensitivity, modestly lowering glucose.